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INTRODUCTION 
Beta-thalassemia is one of the hereditary blood disease in 
which the rate of beta chain generation decreases in 
hemoglobin.1 Today, by advancing in treatment and care 
of children with major thalassemia, their lifetime has been 
increased and regular blood injection in these patients has 
decreased the side effects of anemia and improved their 
growth and maturation.2,3 
Frequent blood transfusions, in spite of having a lot of 
clinical benefits for these patients, it can lead to inevitable 
side effect of Hemosiderosis and may disturb the function 
of tissues as hepatic disorders, heart failure, growth 
disorders, hypogpnadism, hypothyroidism, 
parathyroidism and diabetes and may cause death in 
second or third decade of patient's lifetime.4-6 Each unit of 
Packed RBC includes 250-300mg of iron and patients who 
have received more than 100 units RBC may become 
hemosidrosic. For preventing any above mentioned side 
effects, extra iron has to be removed by deironing methods 
which is conducted by deferoxamine but again the 
disorders of endocrine glands can be observed in these 
people and even some of these side effects have been 
worsen because of patient's long lifetime. 
ABSTRACT 
Background: Beta thalassemia is one of the inherited blood diseases in which 
the production of specific chains in hemoglobin decreases. Esfarlal is a shaltor 
which is used in these patients as a single dose per day. Since it is prescribed 
orally, it is easier to tolerate the drug and control the serum iron level of the 
patient. The aim of this study was to evaluate the efficacy of Osveral in reducing 
ferritin levels in patients with thalassemia major. 
Methods: This quasi-experimental study was performed on 48 patients with 
thalassemia major who referred to Bu-Ali hospital for receiving blood. At the 
beginning of the study, the required data were collected along with patients' tests 
including hemoglobin, ferritin, TSH, T4, CBC diff, BUN AST, ALT, BS and 
creatinine CBC diff. The Osveral drug was prescribed and the patients were 
evaluated monthly for up to 6 months on the basis of complications. In the first 
three months after the start of the drug, the serum ferritin level was measured, the 
dose was adjusted and 6 months after late, the previous tests were again requested, 
and the auditory and visual examinations were performed, and the information 
entered the checklist. Data were analyzed using SPSS statistical software. 
Results: Among all patients, 27 (56.2%) were male and the rest were women 
with a mean age of 22.22 ± 8.77 years. The results showed that during one year 
of study, hemoglobin level increased and ferritin level decreased significantly, 
and other parameters didn’t show significant difference. Nausea and vomiting 
were the most common complications among patients, which was higher after 
Osveral than before receiving Osveral. 
Conclusions: Results showed that Osveral is effective in reducing the level of 
ferritin in patients with thalassemia major, but control of hematuria is 
recommended when using this drug. 
 
Keywords: Ferritin, Major thalassemia, Osveral 
DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20174770 
 
 
 
Department of Pediatrics, 
Faculty of Medicine, Ardabil 
University of Medical Science, 
Ardabil, Iran 
 
Received: 04 September 2017 
Revised: 28 September 2017 
Accepted: 03 October 2017 
 
*Correspondence to: 
Dr. Majid Vafaie, 
Email: m.vafaie@arums.ac.ir 
 
Copyright: © the author(s), 
publisher and licensee Medip 
Academy. This is an open-
access article distributed under 
the terms of the Creative 
Commons Attribution Non-
Commercial License, which 
permits unrestricted non-
commercial use, distribution, 
and reproduction in any 
medium, provided the original 
work is properly cited. 
Fathi A et al. Int J Basic Clin Pharmacol. 2017 Nov;6(11):2556-2560 
                                                          
                 
                     International Journal of Basic & Clinical Pharmacology | November 2017 | Vol 6 | Issue 11    Page 2557 
In the absence of inflammatory diseases, measuring 
ferritin serially is a trustable index and in fact the easiest 
way for evaluating the iron aggregation in body and the 
quality of chalator therapy which indicates the amount of 
iron aggregation in last three months. The decision to long-
term transfusion requires the consumption of iron 
chalators. Deferoxamine is one of well-known iron 
chalators in last decade that is really applicable for these 
patients. This medicine can cause some prevalent side 
effects such as cataract, deafness, growth disorders and 
urticaria.7-9 Although this drug has a vast application but 
because of side effects and its usage (as subcutaneous 
injection), some of patients are not able to tolerate it.  
It is clear that non using another chalator may cause the 
early death of patients.10 
Deferosirox has been evaluated in more than 45 clinical 
trials since 2003. At first this drug known in the market 
with the commercial name of Exjade ® . Single-doze use 
of this medicine per day as 10-40 mg/kg indicated more 
decrease in the concentration rate of hepatic iron toward 
deferoxamine in agent patients and also children. 
Deferosirox can be well tolerated in matures, elderlies and 
children above 2 years old and is used and once a day in 
the form of oral.11-15 
Osveral is the other commercial name of deferosirix which 
is made by an Iranian company and is used as single-doze 
daily. The side effects of this drug include digestive side-
effects (nausea, vomiting, diarrhea, Abdominal pain, 
emphysema and constipation), rash and headache. This 
medicine should not be consumed with anti-acid drug or 
other chalators simultaneously.16 
While Oserval is prescribed by orally and its tolerance and 
control of iron level of patients is done more easily, so the 
aim of this study was to evaluation of efficiency and side 
effects of Oserval in major thalassemia patients of Ardabil 
city. 
METHODS 
This study was conducted in Bu-Ali hospital in Ardabil 
city, Iran. 
Study design 
It was a qusi-experimental study. The information of each 
patients with the results of examination and tests of 
patients (hemoglobin, ferritin level, TSH, T4. CBC diff, 
AST BUN, ALT, BS, and creatinine CBC diff) were 
collected in a checklist. 
Inclusion criteria 
Participants with major thalassemia, age 2-62 years, 
ferritin level up 1000ng/dl, normal creatinine level and 
non-using heart drugs and not having vision or hearing 
problems included in the study.  
Exclusion criteria  
Participants with liver, kidney and heart disease, non-
tolerance to lactose and age >62 years, age <2 years, sever 
skin rash, retinopathy, hearing loss and sensitivity to 
deferoxamine excluded from study. 
Study tools  
The study conducted on 48 patients with major 
thalassemia. The study patients were monthly examined 
during 12 month by considering drug side effects. In the 
first three months after receiving the drug, the serum 
ferritin level was measured, the doze of medicine was 
modified and the before examinations was checked 6 and 
12 months after receiving oserval and also hearing and 
sight examinations is done and the information entered the 
check list. In order to investigate the effect of oserval in 
decreasing the ferritin level, all drugs were stopped if they 
are treating with other chelators (deferoxamine or L1).  
Statistical analysis  
Collected data were analyzed using analytical statistical 
methods such as chi-square and t-test and descriptive 
statistics in form of tables and figures. In all mentioned 
tests, the meaningful level was p<0.05. 
RESULTS 
Of all patients, 27 were male (56.2%) and the rest were 
female. The average age of patients was 20.2±8.8 years old 
and 21 patients (43.8%) were in the age range of 20-30. 
Most of patients with 38 cases had the blood reception 
interval of 3-4 weeks. 13 patients (27.1%) had history of 
splenectomy and 25 (52.1%) had the ferritin level in range 
1000-2000 dl.  
Table 1: Compare the ferritin level in follow-up time 
by groups. 
Time  Group  
Mean±SD 
(mg/dl) 
p-value 
Baseline  
Desferal  2154.5±763 
0.43 
Osveral  2056.8±814 
6 months later 
Desferal  1913.6±822 
0.13 
Osveral  1872.2±848 
End of study (12 
months later) 
Desferal 1718±736 
0.025 
Osveral 1621.7±718 
The Recipients of oserval significantly had more 
hemoglobin level toward Recipients of desferal. 
Prescribed drugs had no effect on placket level of patients 
and the disturbance in urinal examination of osveral 
receiving group was more than other group. The high rate 
of WBC and hemachoric in oserval receiving group 
significantly was more than desferal receiving group. No 
meaningful relationship was found between the creatinine 
level and the type of used drugs in patients. Both groups 
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had the same ferritin level at the baseline and after one year 
of receiving the medicine the ferritin rate in osveral 
receiving group had a meaningful decrease than other 
group (Table 1). 
The side effects in osveral receiving group were 
meaningfully more than desferal receiving group (Table 
2). 
Table 2: Frequency of side-effects by groups. 
Side-effects  
Desferal  Osveral  p-
value  n % n % 
Nausea and 
vomiting  
3 6.3 9 18.9 0.08 
Hearing loss 1 2.1 3 6.3 0.3 
Skin Rash 1 2.1 3 6.3 0.3 
Hematuria 3 6.3 11 23 0.03 
Vision changes 1 2.1 3 6.3 0.3 
DISCUSSION 
In this study, during one year study of the patients, the 
hemoglobin level increased and the ferritin level decreased 
meaningfully and other parameters didn't have meaningful 
difference. In study of Eshghi et al, along with current 
study, there was a meaningfull relationship between 
receiving osveral (iron chalator) and decrease of serum 
ferritin level (p=0.001) but in different age groups the 
difference was not meaningfull. In Keykhaii and et al. 
study the results indicate the meaningful changes of serum 
ferritin level which expresses the high efficiency of oserval 
+ desferal medicine regime.17,18 In study of pormovahed 
and et al, 62.8% of patients were injected deferoxamine 
regularly and there was a meaningful statistical difference 
between the average of height, weight, arm and head 
around in both investigated groups.19 The results indicated 
that the iron discharge is one of the main methods of body 
growth of thalassemic children in the early years of life by 
deferoxamine effectively and it requires the regular blood 
injection. It is observed in study of Ghader Rashidi et al, 
that the deferoxamine injection with high doze can 
decrease the heart symptoms in thalassemin patients 
considerably and improved the systolic operation 
meaningfully but it has no meaningful effect on diastolic 
operation, physical finding and ECG of patients.20 Molavi 
et al, observed along with current study that the one-year 
consumption of osveral can decrease the rate of ferritin in 
thalassemic patients meaningfully.21 Taher et al. indicated 
that defesirox similar to other drugs has same efficiency 
and safety as an iron chalator in beta-thalassemic 
patients.22 It was observed in the study of Cappellini et al, 
which compared the prescription of osveral with four doze 
of 5, 10, 20, 30mg/dl with desferal that the rate of decrease 
of serum iron level in osveral receivers toward desferal 
was meaningful.23 It is also expressed that the decrease rate 
of serum iron level increased considerably with the 
increase of osveral doze (p=0.01). it is also observed in the 
study of Cassinero et al, that one-year regime of 
defroxamine and osveral combination decreased 
significantly the serum iron level form 11.44mg/g dw to 
6.54mg/g dw and serum ferritin level from 2254ng/ml to 
1346ng/ml.24 It was observed in Jasim et al, study that in 
patients receiving desferal and osveral simultaneously, the 
ferritin rate in one year decreased about 23.3% and in 
patients receiving osveral alone this rate decreased about 
18%.25 Arandi et al, observed that patients receiving 
deferoxamin + osveral in one year, the level of ferritin 
serum decreased from 4031 to 2416 meaningfully 
(p=0.001).26 The comparison of results of current study 
with other studies showed that receiving oserval can 
decrease the rate of ferritin level and serum level 
meaningfully and its combination with desferal is more 
effective but present study showed that oserval can have 
more effect than desferal. In present study, nausea and 
vomiting are the most prevalent side-effect and in patients 
after receiving osveral is more than before receiving. 
Eshghi et al, stated that at least 36.4% of patients 
experienced one of the side effects.17 The most prevalent 
side effect of injection is the increase of serum level of 
creatinine and the five time increasing of level of 
transaminases. In keykhaii et al, study, 21% of patients 
experienced at least one of the side effects so that the most 
prevalent side-effect was increase of creatinine level.18 In 
Ghader rashidi et al, study no meaningful side effect was 
observed in deferoxamine receivers.20 Taher et al. 
indicated that side effect was low to medium and was 
eliminated without any additional treatment.22 It was 
observed in Molavi et al study that 11.3% of patients have 
side-effects because of using osveral.21 
Cappellini et al, observed tht 15% of osveral receiving 
were with digestive symptoms and no digestive effects 
were seen in desferal receiving group.22 Piga et al, 
observed that 65.9% of osveral receiving patients are with 
digestive problems, 12.7% with arthropathy and in 
desferal receiving group, 38% of patients with digestive 
side effects and 14% with arthropathy (p=0.04).27 
Cassinerio et al, indicated that no considerable hepatic and 
kidney side-effects were seen in desferal and osveral 
receivers.24 Jasim et al, observed that there is no 
meaningful difference in operational tests of kidney-
hepatic, the number of plackets, sight, hearing, etc. 
between desferal and osveral simultaneously and osveral 
receiving alone.25 Arandi et al, observed that drug 
treatment therapy can not lead to drug side-effects such as 
increasing creatinine, hepatic enzyme and BUN.26 
Haghpanah et al, observed that osveral had more side-
effects than desferal (p=0.4) and in deferoxamine group 
the more prevalent side effect was neurostimulation and 
the pain of injection.28 
CONCLUSION 
The results showed that osveral is a portable iron chelator 
by patients and has effects similar to desferal in decreasing 
serum iron level in patients with iron overload. Osveral 
comparing to desferal has less side effects for patients but 
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it is more effective in decreasing ferritin rate and 
hemoglobin level in major thalassemia patients.  
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